Experimental feature

Listen to this article

Experimental feature

Litigation hurts.

Shares in Indivior are down 11 per cent in early trading after the UK pharmaceutical company earlier revealed a 57 per cent drop in operating profit in 2016 after taking an impairment relating to its ongoing legal issues in the US.

The addiction drug specialist, which was spun off from Reckitt Benckiser in 2014, also warned that the final cost of the litigation could be “materially higher” than the $220m reserve it had put aside so far.

Copyright The Financial Times Limited 2017. All rights reserved.

Follow the topics mentioned in this article

Follow the authors of this article

Comments have not been enabled for this article.